Atropine

Summary

Atropine (CHEMBL517712) is an approved small-molecule muscarinic antagonist (ATC A03BA01) targeting CHRM1, CHRM2, and CHRM3; indicated across 27 conditions including poisoning and myopia.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: A03BA01 (+1 more)
• Targets: 6 (CHRM1, CHRM2, CHRM3…)
• Indications: 27 conditions
• Clinical trials: 141
• Chemistry: 289.4 Da · C17H23NO3

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL517712
Name	Atropine
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	174174
ChEBI	CHEBI:16684
ATC	A03BA01, S01FA01
Molecular formula	C17H23NO3
Molecular weight	289.4
InChIKey	RKUNBYITZUJHSG-PJPHBNEVSA-N

SMILES: CN1[C@@H]2CC[C@H]1CC(C2)OC(=O)C(CO)C3=CC=CC=C3

IUPAC name: [(1S,5R)-8-methyl-8-azabicyclo[3.2.1]octan-3-yl] 3-hydroxy-2-phenylpropanoate

ChEBI definition: A racemate composed of equimolar concentrations of (S)- and (R)-atropine . It is obtained from deadly nightshade (Atropa belladonna) and other plants of the family Solanaceae.

Pharmacological roles (ChEBI): muscarinic antagonist, anaesthesia adjuvant, anti-arrhythmia drug, mydriatic agent, parasympatholytic, bronchodilator agent, antidote to sarin poisoning, oneirogen.

Other ChEBI roles (chemical / environmental): plant metabolite.

Also known as: Atropen, Atropine, Atropine (autoinjector), Atropine component of atnaa, Atropine component of duodote, Atropinum, Atroject, Atrophate, Dl-hyoscyamine, atropine, ATROPINE, SID144204367

Parent form; salt/anhydrous children: CHEMBL1200752, CHEMBL2146146, CHEMBL3182372, CHEMBL3185794

Patent coverage: 17,181 distinct patent families (53,874 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).

Gene	Target	Action	pAffinity	Cancer dependency	UniProt
CHRM1	M1 receptor	Antagonist	9.6	0.2%	P11229
CHRM2	M2 receptor	Antagonist	9.2	0%	P08172
CHRM3	M3 receptor	Antagonist	9.8	0%	P20309
CHRM4	M4 receptor	Antagonist	9.5	1.6%	P08173
CHRM5	M5 receptor	Antagonist	9.3	0%	P08912
ADRA2A	α2A-adrenoceptor	Antagonist	4.85	0.1%	P08913
	Glycine Receptor (All subtypes)	Antagonist	3.6

Broader ChEMBL bioactivity targets: 18 (assay-derived). Sample: Muscarinic acetylcholine receptor M4, Muscarinic acetylcholine receptor, Muscarinic acetylcholine receptor M5, Muscarinic acetylcholine receptor, Muscarinic acetylcholine receptors; M1 & M2, Muscarinic acetylcholine receptor M2, Muscarinic acetylcholine receptor M1, Alpha-1D adrenergic receptor, 5-hydroxytryptamine receptor 2C, Muscarinic acetylcholine receptor M3.

Bioactivity

ChEMBL activities: 116 potent at pChembl ≥ 5 of 117 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
CHRM2	10.3	ED50	0.05	nM	CHEMBL_ACT_624266
CHRM4	9.98	Ki	0.1	nM	CHEMBL_ACT_7613031
P08483	9.92	Ki	0.12	nM	CHEMBL_ACT_239918
CHRM2	9.82	ED50	0.15	nM	CHEMBL_ACT_624265
CHRM5	9.68	Ki	0.21	nM	CHEMBL_ACT_2623395
CHRM1	9.6	Ki	0.25	nM	CHEMBL_ACT_1193802
P08482	9.59	Ki	0.26	nM	CHEMBL_ACT_239916
P08482	9.59	Ki	0.26	nM	CHEMBL_ACT_245902
CHRM1	9.52	Ki	0.3	nM	CHEMBL_ACT_2439800
P08482	9.52	Ki	0.3	nM	CHEMBL_ACT_609602
CHRM2	9.49	Ki	0.32	nM	CHEMBL_ACT_335181
CHRM1	9.48	Ki	0.33	nM	CHEMBL_ACT_148051
CHRM4	9.47	Ki	0.34	nM	CHEMBL_ACT_1193804
P08482	9.47	Ki	0.34	nM	CHEMBL_ACT_578474
P08482	9.47	Ki	0.34	nM	CHEMBL_ACT_609601
Q9ERZ4	9.46	Ki	0.35	nM	CHEMBL_ACT_1191536
P21836	9.46	Ki	0.35	nM	CHEMBL_ACT_1284257
CHRM2	9.46	Ki	0.34	nM	CHEMBL_ACT_148052
CHRM1	9.44	Ki	0.37	nM	CHEMBL_ACT_7613025
CHRM5	9.4	Ki	0.4	nM	CHEMBL_ACT_6356104
CHRM1	9.36	Ki	0.44	nM	CHEMBL_ACT_19122303
CHRM3	9.36	Ki	0.44	nM	CHEMBL_ACT_7613029
P08482	9.35	Ki	0.45	nM	CHEMBL_ACT_62617
P08482	9.34	Ki	0.46	nM	CHEMBL_ACT_578475
P08482	9.34	Ki	0.46	nM	CHEMBL_ACT_609600
P08482	9.32	IC50	0.48	nM	CHEMBL_ACT_5166003
CHRM3	9.3	Ki	0.5	nM	CHEMBL_ACT_1193801
P08482	9.3	Ki	0.5	nM	CHEMBL_ACT_327312
CHRM3	9.28	Ki	0.53	nM	CHEMBL_ACT_19122378
P08485	9.28	Ki	0.52	nM	CHEMBL_ACT_3395364

Target pathways

Aggregated over 6 target gene(s): CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, ADRA2A.

Top Reactome pathways

26 total, by targets touching each:

Pathway	Targets	Genes
Signal Transduction	6	ADRA2A, CHRM1, CHRM2, CHRM3, CHRM4, CHRM5
Signaling by GPCR	6	ADRA2A, CHRM1, CHRM2, CHRM3, CHRM4, CHRM5
Class A/1 (Rhodopsin-like receptors)	6	ADRA2A, CHRM1, CHRM2, CHRM3, CHRM4, CHRM5
Amine ligand-binding receptors	6	ADRA2A, CHRM1, CHRM2, CHRM3, CHRM4, CHRM5
GPCR downstream signalling	6	ADRA2A, CHRM1, CHRM2, CHRM3, CHRM4, CHRM5
GPCR ligand binding	6	ADRA2A, CHRM1, CHRM2, CHRM3, CHRM4, CHRM5
Muscarinic acetylcholine receptors	5	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5
G alpha (q) signalling events	3	CHRM1, CHRM3, CHRM5
G alpha (i) signalling events	3	ADRA2A, CHRM2, CHRM4
Metabolism	2	ADRA2A, CHRM3
Integration of energy metabolism	2	ADRA2A, CHRM3
Regulation of insulin secretion	2	ADRA2A, CHRM3
Hemostasis	1	ADRA2A
Membrane Trafficking	1	CHRM2
Adrenoceptors	1	ADRA2A
Adrenaline signalling through Alpha-2 adrenergic receptor	1	ADRA2A
Metabolism of proteins	1	ADRA2A
Acetylcholine regulates insulin secretion	1	CHRM3
Adrenaline,noradrenaline inhibits insulin secretion	1	ADRA2A
G alpha (z) signalling events	1	ADRA2A
Vesicle-mediated transport	1	CHRM2
Surfactant metabolism	1	ADRA2A
Platelet activation, signaling and aggregation	1	ADRA2A
Platelet Aggregation (Plug Formation)	1	ADRA2A
Cargo recognition for clathrin-mediated endocytosis	1	CHRM2
Clathrin-mediated endocytosis	1	CHRM2

Dominant GO biological processes

GO term	Targets
signal transduction	6
G protein-coupled receptor signaling pathway	6
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger	5
adenylate cyclase-inhibiting G protein-coupled acetylcholine receptor signaling pathway	5
G protein-coupled acetylcholine receptor signaling pathway	5
chemical synaptic transmission	5
phospholipase C-activating G protein-coupled acetylcholine receptor signaling pathway	3
nervous system development	3
acetylcholine receptor signaling pathway	3
regulation of smooth muscle contraction	3
regulation of locomotion	2
saliva secretion	2
adenylate cyclase-inhibiting G protein-coupled receptor signaling pathway	2
presynaptic modulation of chemical synaptic transmission	2
phospholipase C-activating G protein-coupled receptor signaling pathway	1

Indications & clinical

Indications

27 indications (3 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
poisoning	4	MONDO:0029000	EFO:0008546
myopia	3	MONDO:0001384	HP:0000545
strabismus	3	MONDO:0003432	HP:0000486
amblyopia	3	MONDO:0001020	MONDO:0001020
pituitary dwarfism	3	MONDO:0006909	EFO:1001109
anisometropia	3	MONDO:0001478	HP:0012803
degenerative myopia	3	MONDO:0001383	EFO:0004207
seasonal allergic rhinitis	2	MONDO:0005324	EFO:0003956
hypospadias	2	MONDO:0005345	EFO:0004209
blood coagulation disease	2	MONDO:0001531	EFO:0009314
cardiac arrest	2	MONDO:0000745	EFO:0009492
breast neoplasm	2	MONDO:0021100	MONDO:0007254
amyotrophic lateral sclerosis	2	MONDO:0004976	MONDO:0004976
prediabetes syndrome	1	MONDO:0006920	EFO:1001121
orthostatic hypotension	1	MONDO:0005469	EFO:0005252
postural orthostatic tachycardia syndrome	1	MONDO:0011479	EFO:1000645
hypoglycemia	0	MONDO:0004946	HP:0001943

10 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 141.

Phase distribution

Phase	Trials
Not specified	41
PHASE4	40
PHASE3	21
PHASE2	16
PHASE1	8
EARLY_PHASE1	8
PHASE2/PHASE3	5
PHASE1/PHASE2	2

Top trials by phase / activity

NCT	Phase	Status	Title
NCT04641702	PHASE4	RECRUITING	Comprehensive Esophageal Diagnostics Study
NCT05331664	PHASE4	RECRUITING	Dropless Pars Plana Vitrectomy Study
NCT06431841	PHASE4	ACTIVE_NOT_RECRUITING	Atropine and Spectacle Combination Treatment (ASPECT): 12-month Results of a Randomized Clinical Trial for Myopia Control
NCT06450132	PHASE4	ACTIVE_NOT_RECRUITING	Changes in Eye Shape With Myopia Management Interventions
NCT07434635	PHASE4	RECRUITING	APPRAISE: Assessment of Pain and Posterior Synechiae Reduction With Atropine, an Investigation of Post-Surgical Eyes
NCT00094614	PHASE4	COMPLETED	Trial Comparing Daily Atropine Versus Weekend Atropine
NCT00541177	PHASE4	UNKNOWN	Study of Myopia Prevention in Children With Low Concentration of Atropine
NCT00575523	PHASE4	COMPLETED	Atropine for Prevention of Dysrhythmias Caused by Percutaneous Ethanol Instillation for Hepatoma Therapy
NCT00815048	PHASE4	COMPLETED	Remifentanil and Atropine for Intubation in Neonates
NCT00834470	PHASE4	COMPLETED	Adjunctive Atropine During Ketamine Sedation
NCT00921102	PHASE4	COMPLETED	Atropine to Prevent Nausea and Vomiting After Spinal Anesthesia for Caesarean Section
NCT00991627	PHASE4	COMPLETED	Different Approaches to Maternal Hypotension During Cesarean Section
NCT01427985	PHASE4	COMPLETED	Influence of Premedication Protocols for Neonatal Endotracheal Intubation on Cerebral Oxygenation
NCT01539044	PHASE4	COMPLETED	Optimal Relaxation Technique for Laparotomies With Rocuronium Infusion Followed by Sugammadex Reversal
NCT01595399	PHASE4	UNKNOWN	Atropine Versus no Atropine for Neonatal Rapid Sequence Intubation
NCT01761552	PHASE4	UNKNOWN	A Prospective, Randomized Controlled Trial Comparing Traditional Methods of Neuromuscular Block Reversal to Sugammadex for Extubation in the Operating Room in ASA 4 and 4E Patients
NCT01819064	PHASE4	COMPLETED	Heart Rate Response to Atropine Doses Less Than 0.1mg IV to Anesthetized Infants
NCT01845636	PHASE4	COMPLETED	Olfactory Deficits in MCI as Predictor of Improved Cognition on Donepezil
NCT02186132	PHASE4	COMPLETED	0.6 vs. 1.2 mg Atropine Together With Neostigmine 2.5 mg on Heart Rate in Patient Receiving Muscle Relaxant
NCT02215382	PHASE4	COMPLETED	Intraocular Pressure Changes Associated With Tracheal Extubation: Comparison of Sugammadex With Conventional Reversal of Neuromuscular Blockade
NCT02327923	PHASE4	COMPLETED	Intraoperative Lidocaine Infusion vs. Esmolol Infusion for Postoperative Analgesia in Laparoscopic Cholecystectomy
NCT02361060	PHASE4	COMPLETED	Effects of Neuromuscular Block Reversal With Sugammadex vs Neostigmine on Postoperative Respiratory Outcomes After Major Abdominal Surgery
NCT02410590	PHASE4	WITHDRAWN	Rocuronium + Sugammadex vs. Succinylcholine + Cisatracurium + Neostigmine/Atropine in Obese Participants (MK-8616-104)
NCT02445599	PHASE4	COMPLETED	Diclofenac Premedication, as the Effect of Preemptive Analgesia After Post-thoracotomy Chest and Shoulder Pain
NCT02522858	PHASE4	COMPLETED	Anticholinergic Premedication for Sedation With Dexmedetomidine During Spinal Anesthesia
NCT02698969	PHASE4	UNKNOWN	Recovery of Muscle Function After Deep Neuromuscular Block by Means of Diaphragm Ultrasonography
NCT02769325	PHASE4	UNKNOWN	Atropine in Laparoscopic Gynaecological Surgery
NCT03144453	PHASE4	UNKNOWN	Recovery From Anesthesia After Robotic Assisted Radical Cystectomy
NCT03158142	PHASE4	COMPLETED	The Influence of Atropine on Choroidal Thickness
NCT03351608	PHASE4	COMPLETED	Efficacy, Safety, and Pharmacokinetics of Sugammadex for Reversal of Neuromuscular Blockade (NMB) in Pediatric Participants (MK-8616-089)
NCT03544827	PHASE4	COMPLETED	The Effects of Low Dose Atropine on Choroidal Thickness
NCT03580889	PHASE4	UNKNOWN	Atropine Versus Glycopyrrolate in Preventing Spinal Anesthesia Induced Hypotension in Lower Limb Surgeries
NCT03638726	PHASE4	UNKNOWN	Subconjunctival Atropine and Intracameral Epinephrine for Pupil Dilation in Phacoemulsification
NCT03750656	PHASE4	TERMINATED	Use of Hyoscyamine Versus Tamsulosin for Management of Ureteral Stent Irritation
NCT03909165	PHASE4	COMPLETED	Efficacy, Safety, and Pharmacokinetics of Sugammadex (MK-8616) for Reversal of Neuromuscular Blockade in Pediatric Participants Aged Birth to <2 Years (MK-8616-169)
NCT03949101	PHASE4	UNKNOWN	Atropine for Children and Adolescent Myopia Progression Study
NCT03984526	PHASE4	COMPLETED	Atropine or Ephedrine Pretreatment for Preventing Bradycardia in Elderly Patients
NCT05006638	PHASE4	UNKNOWN	Assessing The Role Of Intravenous Lipid Emulsion As A Life Saving Therapy In Pesticides Toxicity
NCT05357326	PHASE4	UNKNOWN	Myopia Intervention in Children and Adolescents and Establishment of a Precise Intervention Model
NCT07406399	PHASE4	COMPLETED	Low Concentration Atropine Combined With Soft Contact Lens in Controlling Myopia Progression in Children With High Myopia

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No CPIC/DPWG dosing guideline or drug-level clinical/variant annotations in PharmGKB for this molecule.

Related molecules

Related molecules

Molecules sharing ≥1 of this drug’s curated primary targets, merged from two biobtree sources and ranked by shared-target count, then clinical phase: ChEMBL clinical-stage candidates (development phase ≥2) and PubChem drug-class bioactivity (approved / known drugs acting on the target). Deduplicated by drug name; the drug’s own salt forms are excluded. Note: for a drug with few primary targets a shared-target match can reflect off-target / promiscuous binding rather than the same therapeutic mechanism — the phase ordering surfaces bona-fide therapeutics first.

762 molecules share ≥1 primary target. Top 60 by shared-target count:

Molecule	Source	Status	Shared targets
ACLIDINIUM BROMIDE	ChEMBL + PubChem	Phase 4 (approved)	ADRA2A, CHRM1, CHRM2, CHRM3, CHRM4, CHRM5
CLOZAPINE	ChEMBL + PubChem	Phase 4 (approved)	ADRA2A, CHRM1, CHRM2, CHRM3, CHRM4, CHRM5
DESLORATADINE	ChEMBL + PubChem	Phase 4 (approved)	ADRA2A, CHRM1, CHRM2, CHRM3, CHRM4, CHRM5
GENTIAN VIOLET	ChEMBL + PubChem	Phase 4 (approved)	ADRA2A, CHRM1, CHRM2, CHRM3, CHRM4, CHRM5
Mavorixafor	ChEMBL + PubChem	Phase 4 (approved)	ADRA2A, CHRM1, CHRM2, CHRM3, CHRM4, CHRM5
OLANZAPINE	ChEMBL + PubChem	Phase 4 (approved)	ADRA2A, CHRM1, CHRM2, CHRM3, CHRM4, CHRM5
AMIODARONE	ChEMBL	Phase 4 (approved)	ADRA2A, CHRM1, CHRM2, CHRM3, CHRM4, CHRM5
AMITRIPTYLINE	ChEMBL	Phase 4 (approved)	ADRA2A, CHRM1, CHRM2, CHRM3, CHRM4, CHRM5
AMOXAPINE	ChEMBL	Phase 4 (approved)	ADRA2A, CHRM1, CHRM2, CHRM3, CHRM4, CHRM5
ASTEMIZOLE	ChEMBL	Phase 4 (approved)	ADRA2A, CHRM1, CHRM2, CHRM3, CHRM4, CHRM5
BENZTROPINE	ChEMBL	Phase 4 (approved)	ADRA2A, CHRM1, CHRM2, CHRM3, CHRM4, CHRM5
CHLOROQUINE	ChEMBL	Phase 4 (approved)	ADRA2A, CHRM1, CHRM2, CHRM3, CHRM4, CHRM5
CHLORPROMAZINE	ChEMBL	Phase 4 (approved)	ADRA2A, CHRM1, CHRM2, CHRM3, CHRM4, CHRM5
CINNARIZINE	ChEMBL	Phase 4 (approved)	ADRA2A, CHRM1, CHRM2, CHRM3, CHRM4, CHRM5
CLEMASTINE	ChEMBL	Phase 4 (approved)	ADRA2A, CHRM1, CHRM2, CHRM3, CHRM4, CHRM5
CLOMIPRAMINE	ChEMBL	Phase 4 (approved)	ADRA2A, CHRM1, CHRM2, CHRM3, CHRM4, CHRM5
CYCLIZINE	ChEMBL	Phase 4 (approved)	ADRA2A, CHRM1, CHRM2, CHRM3, CHRM4, CHRM5
CYPROHEPTADINE	ChEMBL	Phase 4 (approved)	ADRA2A, CHRM1, CHRM2, CHRM3, CHRM4, CHRM5
DARIFENACIN	ChEMBL	Phase 4 (approved)	ADRA2A, CHRM1, CHRM2, CHRM3, CHRM4, CHRM5
DEXCHLORPHENIRAMINE	ChEMBL	Phase 4 (approved)	ADRA2A, CHRM1, CHRM2, CHRM3, CHRM4, CHRM5
DIMENHYDRINATE	ChEMBL	Phase 4 (approved)	ADRA2A, CHRM1, CHRM2, CHRM3, CHRM4, CHRM5
DIPHENHYDRAMINE	ChEMBL	Phase 4 (approved)	ADRA2A, CHRM1, CHRM2, CHRM3, CHRM4, CHRM5
DOXEPIN	ChEMBL	Phase 4 (approved)	ADRA2A, CHRM1, CHRM2, CHRM3, CHRM4, CHRM5
EBASTINE	ChEMBL	Phase 4 (approved)	ADRA2A, CHRM1, CHRM2, CHRM3, CHRM4, CHRM5
HALOPERIDOL	ChEMBL	Phase 4 (approved)	ADRA2A, CHRM1, CHRM2, CHRM3, CHRM4, CHRM5
HYDROXYCHLOROQUINE	ChEMBL	Phase 4 (approved)	ADRA2A, CHRM1, CHRM2, CHRM3, CHRM4, CHRM5
KETOTIFEN	ChEMBL	Phase 4 (approved)	ADRA2A, CHRM1, CHRM2, CHRM3, CHRM4, CHRM5
LOXAPINE	ChEMBL	Phase 4 (approved)	ADRA2A, CHRM1, CHRM2, CHRM3, CHRM4, CHRM5
MAPROTILINE	ChEMBL	Phase 4 (approved)	ADRA2A, CHRM1, CHRM2, CHRM3, CHRM4, CHRM5
MEPAZINE	ChEMBL	Phase 4 (approved)	ADRA2A, CHRM1, CHRM2, CHRM3, CHRM4, CHRM5
MIANSERIN	ChEMBL	Phase 4 (approved)	ADRA2A, CHRM1, CHRM2, CHRM3, CHRM4, CHRM5
NORTRIPTYLINE	ChEMBL	Phase 4 (approved)	ADRA2A, CHRM1, CHRM2, CHRM3, CHRM4, CHRM5
ORPHENADRINE	ChEMBL	Phase 4 (approved)	ADRA2A, CHRM1, CHRM2, CHRM3, CHRM4, CHRM5
OXYBUTYNIN	ChEMBL	Phase 4 (approved)	ADRA2A, CHRM1, CHRM2, CHRM3, CHRM4, CHRM5
PERHEXILINE	ChEMBL	Phase 4 (approved)	ADRA2A, CHRM1, CHRM2, CHRM3, CHRM4, CHRM5
PROCHLORPERAZINE	ChEMBL	Phase 4 (approved)	ADRA2A, CHRM1, CHRM2, CHRM3, CHRM4, CHRM5
PROMAZINE	ChEMBL	Phase 4 (approved)	ADRA2A, CHRM1, CHRM2, CHRM3, CHRM4, CHRM5
PROMETHAZINE	ChEMBL	Phase 4 (approved)	ADRA2A, CHRM1, CHRM2, CHRM3, CHRM4, CHRM5
QUETIAPINE	ChEMBL	Phase 4 (approved)	ADRA2A, CHRM1, CHRM2, CHRM3, CHRM4, CHRM5
QUINACRINE	ChEMBL	Phase 4 (approved)	ADRA2A, CHRM1, CHRM2, CHRM3, CHRM4, CHRM5
RISPERIDONE	ChEMBL	Phase 4 (approved)	ADRA2A, CHRM1, CHRM2, CHRM3, CHRM4, CHRM5
SERTRALINE	ChEMBL	Phase 4 (approved)	ADRA2A, CHRM1, CHRM2, CHRM3, CHRM4, CHRM5
SULOCTIDIL	ChEMBL	Phase 4 (approved)	ADRA2A, CHRM1, CHRM2, CHRM3, CHRM4, CHRM5
TAMOXIFEN	ChEMBL	Phase 4 (approved)	ADRA2A, CHRM1, CHRM2, CHRM3, CHRM4, CHRM5
TERCONAZOLE	ChEMBL	Phase 4 (approved)	ADRA2A, CHRM1, CHRM2, CHRM3, CHRM4, CHRM5
THIORIDAZINE	ChEMBL	Phase 4 (approved)	ADRA2A, CHRM1, CHRM2, CHRM3, CHRM4, CHRM5
XANOMELINE	ChEMBL	Phase 4 (approved)	ADRA2A, CHRM1, CHRM2, CHRM3, CHRM4, CHRM5
DIMETHINDENE	ChEMBL	Phase 3	ADRA2A, CHRM1, CHRM2, CHRM3, CHRM4, CHRM5
ENCLOMIPHENE	ChEMBL	Phase 3	ADRA2A, CHRM1, CHRM2, CHRM3, CHRM4, CHRM5
BENZETHONIUM CHLORIDE	ChEMBL	Phase 2	ADRA2A, CHRM1, CHRM2, CHRM3, CHRM4, CHRM5
FLUNARIZINE	ChEMBL	Phase 2	ADRA2A, CHRM1, CHRM2, CHRM3, CHRM4, CHRM5
ACETYLCHOLINE	ChEMBL	Phase 4 (approved)	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5
BETHANECHOL	ChEMBL	Phase 4 (approved)	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5
CARBACHOL	ChEMBL	Phase 4 (approved)	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5
CARBAMOYLCHOLINE	ChEMBL	Phase 4 (approved)	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5
CARIPRAZINE	ChEMBL	Phase 4 (approved)	ADRA2A, CHRM1, CHRM2, CHRM4, CHRM5
CLIDINIUM	ChEMBL	Phase 4 (approved)	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5
CLOTRIMAZOLE	ChEMBL	Phase 4 (approved)	ADRA2A, CHRM1, CHRM2, CHRM3, CHRM4
DICYCLOMINE	ChEMBL	Phase 4 (approved)	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5
DIPHENIDOL	ChEMBL	Phase 4 (approved)	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5